BioElectronics Company Update July 7, 2016

  • July 8th, 2016
  • News
  • 0 Comments
  • Adam Staelin

BioElectronics Expands Pulsed Shortwave Technology Thursday, July 7, 2016 Dr. Sree Koneru, our Director of Electroceutical Research working at the Clinical Science and Engineering Research Center, New York State University, Binghamton, New York,  has made significant advances in our understanding and development of pulsed shortwave technology. A series of experiments using a unique testing device […]

BioElectronics Company Update – June 8, 2016

  • June 9th, 2016
  • News
  • 0 Comments
  • Adam Staelin

US FDA Meeting On May 24, 2016, we met with FDA reviewer for our ActiPatch device, key management from the Physical Medicine and Neurotherapeutic Devices Branch, senior leadership from the Division of Neurological and Physical Medicine Devices, and a Regulatory Advisor, Office of Device Evaluation. BioElectronics Attendees: Richard Staelin, PhD, Chairman of Board, PhD in […]

Bioelectronics Compay Update April 7, 2016

  • April 7th, 2016
  • News
  • 0 Comments
  • Adam Staelin

BioElectronics Wins “Best OTC Marketing Campaign on a Small Budget” The OTC Bulletin, the leading global trade publication for over-the-counter healthcare products, has chosen ActiPatch® Musculoskeletal Chronic Pain Relief Therapy as the winner for the “Best OTC Marketing Campaign on a Small Budget” award. A panel of six independent over-the-counter marketing experts evaluated the seven […]

BioElectronics Drug-free Chronic Pain Therapy Observation Study Results

  • March 29th, 2016
  • News
  • 0 Comments
  • bfichter

61% Pain Reduction & Decreases Medication Use in 86% (including opioids) FREDERICK, MD, USA, March 29, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of the drug-free over-the-counter, $30.00 ActiPatch® (www.actipatch.com) Musculoskeletal Pain Therapy medical devices, announced today the completion of a 6-month ActiPatch product observation study conducted in conjunction with its ongoing market […]

BioElectronics and B. Braun Medical Ltd Apply for Prescription Payment Clearance on the UK Drug Tariff

  • February 18th, 2016
  • News
  • 0 Comments
  • bfichter

FREDERICK, MD. Feb 18, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that B. Braun has initiated the application for a listing of RecoveryRx® on the National Health Service (NHS) drug tariff (http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx).The UK drug tariff list establishes payment for prescription costs in the UK. “Orthopedic surgeons […]

BioElectronics Corporation Refutes SEC Order for Administrative Proceedings

  • February 8th, 2016
  • News
  • 0 Comments
  • bfichter

FREDERICK, Md., Feb. 8, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that it is responding to a notice of an order for administrative proceedings from the Securities and Exchange Commission posted on the agency website. “Although neither the Company nor any of the respondents have been […]

BioElectronics’ Innovative Chronic Pain Therapy Nominated for “Best OTC Marketing Campaign on a Small Budget”

  • February 1st, 2016
  • News
  • 0 Comments
  • bfichter

FREDERICK, MD. February 1, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced today that its ActiPatch® Musculoskeletal Pain Relief Therapy product received an award nomination from the OTC Bulletin, the leading international trade publication for over-the-counter pharmacy products worldwide for “Best OTC Marketing Campaign on a Small Budget”. The […]

BioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis

  • January 5th, 2016
  • News
  • 0 Comments
  • bfichter

FREDERICK, MD. January 5, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced publication of a clinical study demonstrating the efficacy of ActiPatch® Therapy for knee osteoarthritis. This study further validates the positive effects of negating chronic pain central sensitization¹ by ActiPatch® noninvasive neuromodulation therapy. The technology is affordable, effective, […]

BioElectronics Announces Oxford University Sponsored Study

  • December 14th, 2015
  • News
  • 0 Comments
  • bfichter

ActiPatch® Therapy for Chronic Low Back Pain FREDERICK, MD. Dec 14, 2015 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, today announced that Oxford University is sponsoring a clinical trial on chronic lower back pain using ActiPatch® Therapy. Chronic low back pain is a major health problem and has significant […]

BioElectronics’ ActiPatch® Pain Therapy Available at 102 Showcase Stores in Canada

  • December 7th, 2015
  • News
  • 0 Comments
  • bfichter

FREDERICK, MD. December 7, 2015 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer pain management medical devices, today announced that its Canadian distributor, Chris-Kelly LLC, has shipped the initial stocking order to Showcase stores. Chris Russell, President, Chris-Kelly, LLC, stated, “We are excited to have a retail partner like Showcase only eight […]